Pulmonary Embolism Therapeutic Pipeline Market Drugs and Companies Review H2 2014

Share Article

RnRMarketReserach.com adds Pulmonary Embolism – Pipeline Review, H2 2014 to its store. The analysis provides an overview of the Pulmonary Embolism’s therapeutic pipeline.

Pulmonary Embolism Therapeutic Pipeline Market

Pulmonary Embolism Therapeutic Pipeline Market

The report “Pulmonary Embolism – Pipeline Review, H2 2014” provides comprehensive information on the therapeutic development for Pulmonary Embolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Embolism and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/pulmonary-embolism-pipeline-review-h2-2014-market-report.html .

Lung embolism is when one or more pulmonary bloodstream in your respiratory system become obstructed. In most cases, pulmonary embolism is due to blood clotting that travel to the respiratory system from the feet or hardly ever other parts of the body. Companies discussed in this Pulmonary Embolism – Pipeline Review, H2 2014 report include Bayer AG, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, F. Hoffmann-La Roche Ltd.

Drugs profile discussed in this Pulmonary Embolism – Pipeline Review, H2 2014 report include apixaban, edoxaban tosylate, rivaroxaban, Small Molecule for Pulmonary Embolism and Hematological Disorders, SMTP-7, TRX-1. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=244993 .

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pulmonary Embolism
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pulmonary Embolism and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pulmonary Embolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pulmonary Embolism pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Inquire before Buying @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=244993 . (This is a premium report priced at US$2000 for a single user License.)

Major points in Table of Content
List of Tables
Number of Products under Development for Pulmonary Embolism, H2 2014 7
Number of Products under Development for Pulmonary Embolism - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Pulmonary Embolism - Pipeline by Bayer AG, H2 2014 16
Pulmonary Embolism - Pipeline by Bristol-Myers Squibb Company, H2 2014 17
Pulmonary Embolism - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 18
Pulmonary Embolism - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 26
Pulmonary Embolism Therapeutics - Recent Pipeline Updates, H2 2014 38
Pulmonary Embolism - Dormant Projects, H2 2014 58
Pulmonary Embolism - Discontinued Products, H2 2014 59

List of Figures
Number of Products under Development for Pulmonary Embolism, H2 2014 7
Number of Products under Development for Pulmonary Embolism - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Early Stage Products, H2 2014 13
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Top 10 Targets, H2 2014 21
Number of Products by Stage and Top 10 Targets, H2 2014 22
Number of Products by Top 10 Mechanism of Actions, H2 2014 23
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 24
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 25
Number of Products by Stage and Top 10 Molecule Types, H2 2014 26

Explore more reports on Pharmaceuticals industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@chinamrreport
Follow >
Market Reports China
Like >
Follow us on
Visit website